Contractors open shop; India checks its exporters;

> NextPharma's Sterile Product Development Center outside of Brussels is now in business, having shipped its first formulated, manufactured and labeled GMP drug candidate for the trial of a controlled-release, anhydrous and lipid based formulation. Release

> Waymade Healthcare has cut the ribbon on a specialty-medication manufacturing facility, targeting drugs made for patients with such special needs as allergies to common pharma ingredients. Article

> Regulators in India are clamping down on drug exporters. Blog

> Berlin-based process-management solutions provider Pumacy Technologies has developed the KMmaster Life Science Edition as part of the EU's BIOsecure project for quality assurance. Release

> MWB Consulting, which advises international clients on development and postmarketing support of pharmaceuticals and medical devices, has joined SAFE-BioPharma Association. Announcement

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.